AstraZeneca
Tracked across 21 events · 277 articles · First seen Jan 08, 2025 · Last active Jul 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: AstraZeneca, as HUTCHMED's partner, jointly developed and commercializes ORPATHYS (savolitinib). The approval in China for gastric cancer expands its market reach and reinforces its precision medicine strategy.
Jul 02, 2026 · 6 articles
International
Impact: AstraZeneca announced a significant investment of $15 billion in China through 2030 to expand its medicines manufacturing and research, demonstrating confidence in the Chinese market.
Jan 30, 2026 · 9 articles
International
Impact: AstraZeneca featured an AI-powered drug discovery platform, advancing precision diagnostics and treatment.
Jun 15, 2026 · 87 articles
Tech
Impact: AstraZeneca has partnered with Quell Therapeutics to develop therapies for inflammatory bowel disease, indicating its interest in the field of immune tolerance.
Oct 06, 2025 · 6 articles
Business
Impact: AstraZeneca is a recipient of the 2026 Visionary Growth Leadership Best Practices Recognition, which could positively influence its brand image and investor perception.
Jun 15, 2026 · 6 articles
Business
Impact: Maria G. Belvisi previously served as Senior Vice President, Research & Development, Respiratory & Immunology at AstraZeneca, where she led the development of tozorakimab.
Apr 10, 2026 · 6 articles
Domestic
Impact: AstraZeneca, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Regulatory
Impact: AstraZeneca, like Pfizer, previously agreed to lower prescription drug costs for United States — Medicaid, contributing to the broader context of the Trump administration's efforts to control drug prices.
Nov 06, 2025 · 6 articles
International
Impact: AstraZeneca's CEO, Pascal Soriot, is part of the business delegation, suggesting potential for increased pharmaceutical and healthcare sector cooperation with China.
Jan 27, 2026 · 34 articles
Regulatory
Impact: AstraZeneca is mentioned as a collaborator with Innate Pharma, specifically on the monalizumab antibody.
Apr 02, 2026 · 7 articles
Business
Impact: AstraZeneca is mentioned as a collaborator with Innate Pharma, specifically on the monalizumab antibody for non-small cell lung cancer.
Apr 08, 2026 · 6 articles
Regulatory
Impact: AstraZeneca is mentioned as a biopharmaceutical company with whom Innate Pharma has established collaborations, including the development of monalizumab.
Apr 13, 2026 · 6 articles
Business
Impact: AstraZeneca is mentioned as one of the industry leaders that Kaltura and PathFactory already serve.
Apr 17, 2026 · 7 articles
70
AstraZeneca commercializesORPATHYS Approved for...
60
AstraZeneca featured platform4th China International...
+ 6 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track AstraZeneca live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard